SPECIFIC ANTIDOTES TO NEW ORAL ANTICOAGULANTS
Safety profiles of the novel oral anticoagulants (NOAC) (rivaroxaban, apixaban, edoxaban, dabigatran) are better than that of warfarin. However, the risk (including lifethreatening) of bleeding is no less than 2.3-3.1% per year. Three specific antidotes to NOAC are currently in different phases...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Kirja |
| Julkaistu: |
«REMEDIUM GROUP» Ltd.,
2016-07-01T00:00:00Z.
|
| Aiheet: | |
| Linkit: | Connect to this object online. |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|
Internet
Connect to this object online.3rd Floor Main Library
| Hyllypaikka: |
A1234.567 |
|---|---|
| Nide 1 | Saatavissa |